Open AccessPre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study
Author(s) -
Ying L. Liu,
Qin Zhou,
Alexia Iasonos,
S. Dennis,
Oliver Zivanovic,
Yukio Sonoda,
Ginger J. Gardner,
Vance Broach,
Roisin E. O’Cearbhaill,
Jason Konner,
Rachel N. Grisham,
Carol Aghajanian,
Nadeem R. AbuRustum,
William P. Tew,
Kara Long Roche
Publication year - 2020
Publication title -
international journal of gynecological cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.901
H-Index - 87
eISSN - 1525-1438
pISSN - 1048-891X
DOI - 10.1136/ijgc-2020-001641
Subject(s) - medicine , debulking , neoadjuvant therapy , oncology , chemotherapy , cancer , ovarian cancer , surgery , breast cancer
Although trials of neoadjuvant chemotherapy in ovarian cancer use 3 neoadjuvant cycles, real-world practice varies. We sought to evaluate the influence of increasing pre-operative cycles on survival, accounting for surgical outcomes.